PDI inks one-year sales agreement

Share this article:
Contract sales firm PDI has inked a one-year sales agreement for a cardiology drug with an unnamed “top-10 pharmaceutical company.”

The initiative, expected to bring in $13 million in revenue, will target primary care physicians and cardiologists and was scheduled to begin April 2.

The announcement is viewed as a much-needed boost for PDI, which announced a decision by a “large pharma company” client not to renew a $35 million contract sales engagement with the firm. PDI previously expected that one-year deal to be extended through the end of 2007.

PDI has endured four major contract losses during the past year.

Share this article:

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.